OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥8,284,510 | ¥8,617,512 | ¥7,600,687 | ¥6,792,995 |
| - Cash | ¥1,675,223 | ¥1,228,091 | ¥833,883 | ¥945,000 |
| + Debt | ¥23,212 | ¥37,140 | ¥51,067 | ¥64,995 |
| Enterprise Value | ¥6,632,499 | ¥7,426,561 | ¥6,817,871 | ¥5,912,990 |
| Revenue | ¥230,406 | ¥201,485 | ¥186,750 | ¥338,000 |
| % Growth | 14.4% | 7.9% | -44.7% | – |
| Gross Profit | ¥32,592 | -¥3,534 | ¥11,066 | ¥40,419 |
| % Margin | 14.1% | -1.8% | 5.9% | 12% |
| EBITDA | -¥239,898 | -¥313,497 | -¥115,252 | -¥170,665 |
| % Margin | -104.1% | -155.6% | -61.7% | -50.5% |
| Net Income | -¥240,766 | -¥314,365 | -¥98,053 | -¥172,000 |
| % Margin | -104.5% | -156% | -52.5% | -50.9% |
| EPS Diluted | -0.76 | -1.13 | -0.36 | -0.63 |
| % Growth | 32.7% | -213.9% | 42.9% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |